In conclusion, the combination of camrelizumab, albumin-bound paclitaxel, and S-1 as first-line treatment for patients with HER2-negative advanced G/GEJ adenocarcinoma showed promising efficacy and an acceptable safety profile. This evidence concerns the gene ALB and gastroesophageal junction adenocarcinoma.